DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Raloxifene Hydrochloride is a drug marketed by Amneal Pharms, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Glenmark Pharms Ltd, Invagen Pharms, Sciegen Pharms Inc, Teva Pharms Usa, and Watson Labs Inc. and is included in eight NDAs.
The generic ingredient in RALOXIFENE HYDROCHLORIDE is raloxifene hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.
A generic version of RALOXIFENE HYDROCHLORIDE was approved as raloxifene hydrochloride by TEVA PHARMS USA on March 4th, 2014.
Recent Clinical Trials for RALOXIFENE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
|Monash Health||Phase 4|
|Massachusetts General Hospital||Phase 4|
|Laboratorios Grossman, S.A.||Phase 3|